Diagnosis, Severity, and Prognosis from Potential Biomarkers of COVID-19 in Urine: A Review of Clinical and Omics Results
2024

Potential Urine Biomarkers for COVID-19 Diagnosis and Prognosis

Sample size: 45 publication 10 minutes Evidence: moderate

Author Information

Author(s): Jennifer Narro-Serrano, Frutos Carlos Marhuenda-Egea

Primary Institution: University of Alicante

Hypothesis

Can urine biomarkers provide insights into the diagnosis, severity, and prognosis of COVID-19?

Conclusion

Urinary biomarkers can help diagnose COVID-19 and assess its severity and prognosis.

Supporting Evidence

  • Urine is a non-invasive sample that can be collected frequently for biomarker analysis.
  • Identified biomarkers include kynurenine, neopterin, and ACE2, which reflect disease severity.
  • Urinary biomarkers can provide insights into metabolic stress and renal dysfunction in COVID-19 patients.
  • Standardized protocols are needed to improve the reliability of urine-based diagnostics.

Takeaway

Scientists are looking at urine to find clues about COVID-19, which can help doctors know how sick someone is and how to treat them.

Methodology

This review analyzed 45 studies on urine biomarkers for COVID-19 using various omics and clinical analyses.

Potential Biases

Many studies focused on specific cohorts, limiting generalizability to broader populations.

Limitations

The studies varied widely in methodologies and sample sizes, which complicates direct comparisons.

Participant Demographics

The studies included diverse populations, but many were hospitalized or critically ill patients.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/metabo14120724

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication